1. 99mTc-PSMA SPECT/CT Versus 68Ga-PSMA PET/CT in the Evaluation of Metastatic Prostate Cancer
- Author
-
Davood Beiki, Babak Fallahi, Najme Karamzade-Ziarati, Alireza Emami-Ardekani, Mohammad Eftekhari, Armaghan Fard-Esfahani, Niloufar Khademi, and Saeed Farzanefar
- Subjects
Male ,Single Photon Emission Computed Tomography Computed Tomography ,Gallium Radioisotopes ,urologic and male genital diseases ,030218 nuclear medicine & medical imaging ,03 medical and health sciences ,Prostate cancer ,0302 clinical medicine ,Positron Emission Tomography Computed Tomography ,Organometallic Compounds ,Humans ,Medicine ,Radiology, Nuclear Medicine and imaging ,In patient ,Neoplasm Metastasis ,Gallium Isotopes ,Aged ,Membrane antigen ,Aged, 80 and over ,PET-CT ,Membrane Glycoproteins ,business.industry ,68ga psma ,Prostatic Neoplasms ,Imaging Procedures ,General Medicine ,Middle Aged ,medicine.disease ,IV injection ,Prostate Bed ,030220 oncology & carcinogenesis ,business ,Nuclear medicine - Abstract
Background 99mTc-prostate-specific membrane antigen (PSMA) SPECT/CT is less expensive and readily available modality compared with 68Ga-PSMA PET/CT for imaging prostate cancer (PC). The aim of this study is to compare the value of these 2 modalities in patients confirmed or suspicious to have metastatic prostate cancer. Patients and methods Twenty-two patients with the mean age of 66.6 ± 10.1 years were studied using 99mTc-PSMA SPECT/CT and 68Ga-PSMA PET/CT, with less than 7 days interval between the 2 imaging procedures. Whole-body PET/CT was done 60 minutes after IV injection of 185 MBq (5 mCi) of 68Ga-PSMA. 99mTc-PSMA SPECT/CT was performed 3 hours after IV injection of 555 to 740 MBq (15-20 mCi) of 99mTc-PSMA. The images of each modality were interpreted independently, and the results were compared according to patient-based as well as region-based analyses. Results In patient-based evaluation, both 99mTc-PSMA SPECT/CT and 68Ga-PSMA PET/CT scans were positive in 95.45% (21/22). In region-based evaluation, 68Ga-PSMA PET/CT detected 53 regions (median of 2 regions per patient; range, 0-5), whereas 43 (median of 2 regions per patient; range, 0-5) were detected by 99mTc-PSMA SPECT/CT. Most of these differences could be explained by lower detection rate of 99mTc-PSMA SPECT/CT in prostate bed (n = 6). PET/CT detected more involved regions than SPECT/CT (P = 0.007), whereas similar frequency of extraprostatic lesions were diagnosed in both modalities (P = 0.102). Significant correlation was also demonstrated between serum prostate-specific antigen level and imaging parameters of disease extension detected by 2 modalities. Conclusions 99mTc-PSMA SPECT/CT could be a potential substitute for 68Ga-PSMA PET/CT in high-risk patients, except when evaluation of prostate bed is of major concern.
- Published
- 2020
- Full Text
- View/download PDF